Depression, Postpartum

Neurology
1
Pipeline Programs
2
Companies
4
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Biogen
BiogenCAMBRIDGE, MA
2 programs
1
SAGE-217Phase 31 trial
ZuranoloneN/A2 trials
Active Trials
NCT07047820Recruiting200Est. Aug 2026
NCT05655507Completed19Est. Oct 2024
NCT04442503Completed200Est. Apr 2022
Neuronetics
NeuroneticsMALVERN, PA
1 program
NeuroStar Transcranial Magnetic StimulationN/A1 trial
Active Trials
NCT01842542Terminated25Est. Aug 2015

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
BiogenSAGE-217
BiogenZuranolone
BiogenZuranolone
NeuroneticsNeuroStar Transcranial Magnetic Stimulation

Clinical Trials (4)

Total enrollment: 444 patients across 4 trials

A Study to Evaluate the Efficacy and Safety of SAGE-217 in Participants With Severe Postpartum Depression (PPD)

Start: Jun 2020Est. completion: Apr 2022200 patients
Phase 3Completed

Zuranolone Pharmacokinetics (PK) and Safety Study Adolescent Participants With Major Depressive Disorder (MDD)

Start: Apr 2023Est. completion: Oct 202419 patients
Phase 1Completed

A Study to Learn More About How Zuranolone Affects Postpartum Depression Symptoms in Participants Who Took it Within 1 Year After The End of Their Pregnancy

Start: Jun 2025Est. completion: Aug 2026200 patients
N/ARecruiting
NCT01842542NeuroneticsNeuroStar Transcranial Magnetic Stimulation

Efficacy and Safety Study of NeuroStar TMS Therapy in Patients With Major Depressive Disorder With Postpartum Onset

Start: Dec 2013Est. completion: Aug 201525 patients
N/ATerminated

Related Jobs in Neurology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 444 patients
2 companies competing in this space